Acute generalized exanthematous pustulosis after COVID-19 treatment with hydroxychloroquine.
作者信息
Litaiem Noureddine, Hajlaoui Khaoula, Karray Manel, Slouma Maroua, Zeglaoui Faten
机构信息
Department of Dermatology, Charles Nicolle Hospital, Tunis, Tunisia.
Faculty of Medicine of Tunis, University of Tunis El Manar, Tunis, Tunisia.
出版信息
Dermatol Ther. 2020 Jul;33(4):e13565. doi: 10.1111/dth.13565. Epub 2020 May 26.
Abstract
摘要
相似文献
1
Acute generalized exanthematous pustulosis after COVID-19 treatment with hydroxychloroquine.
Dermatol Ther. 2020 Jul;33(4):e13565. doi: 10.1111/dth.13565. Epub 2020 May 26.
2
Acute generalized exanthematous pustulosis induced by hydroxychloroquine prescribed for COVID-19.
J Allergy Clin Immunol Pract. 2020 Sep;8(8):2777-2779.e1. doi: 10.1016/j.jaip.2020.05.046. Epub 2020 Jun 7.
3
Generalized pustular figurate erythema: A newly delineated severe cutaneous drug reaction linked with hydroxychloroquine.
Dermatol Ther. 2020 May;33(3):e13380. doi: 10.1111/dth.13380. Epub 2020 Apr 16.
4
Acute generalized exanthematous pustulosis and Stevens-Johnson syndrome overlap due to hydroxychloroquine: a case report.
J Med Case Rep. 2020 Nov 3;14(1):210. doi: 10.1186/s13256-020-02504-8.
5
Facts, not Fear: Safety of Hydroxychloroquine.
Am J Med Sci. 2020 Aug;360(2):199-200. doi: 10.1016/j.amjms.2020.05.003. Epub 2020 May 11.
6
Delayed Presentation of Acute Generalized Exanthematous Pustulosis Following Treatment with Cefepime in a Patient with COVID-19 without the Use of Hydroxychloroquine.
Am J Case Rep. 2020 Oct 24;21:e926901. doi: 10.12659/AJCR.926901.
7
Acute generalized exanthematous pustulosis induced by empiric hydroxychloroquine for presumed COVID-19.
Dermatol Ther. 2020 Nov;33(6):e13834. doi: 10.1111/dth.13834. Epub 2020 Jul 8.
8
Acute generalized exanthematous pustulosis with erythema multiforme-like lesions induced by Hydroxychloroquine in a woman with coronavirus disease 2019 (COVID-19).
J Eur Acad Dermatol Venereol. 2020 Sep;34(9):e457-e459. doi: 10.1111/jdv.16613. Epub 2020 Jul 3.
9
Hydroxychloroquine and ivermectin: A synergistic combination for COVID-19 chemoprophylaxis and treatment?
J Am Acad Dermatol. 2020 Jun;82(6):e221. doi: 10.1016/j.jaad.2020.04.017. Epub 2020 Apr 10.
10
A case of cefditoren-induced acute generalized exanthematous pustulosis during COVID-19 pandemics. Severe cutaneous adverse reactions are an issue.
J Eur Acad Dermatol Venereol. 2020 Oct;34(10):e537-e539. doi: 10.1111/jdv.16664. Epub 2020 Jul 2.
引用本文的文献
1
Mucocutaneous presentations of consultant critical and non-critical cases of admitted COVID-19 patients, outpatients, and vaccine-associated dermatoses: a clinical atlas and a large original study of two general COVID-19 centers from Iran.
Dermatol Reports. 2023 May 23;15(2):9473. doi: 10.4081/dr.2023.9473. eCollection 2023 Jun 7.
2
A case of acute generalized exanthematous pustulosis following COVID-19 infection and remdesivir.
Clin Case Rep. 2023 May 29;11(6):e7423. doi: 10.1002/ccr3.7423. eCollection 2023 Jun.
3
Acute Generalized Exanthematous Pustulosis: Clinical Features, Differential Diagnosis, and Management.
Am J Clin Dermatol. 2023 Jul;24(4):557-575. doi: 10.1007/s40257-023-00779-3. Epub 2023 May 8.
4
Clinical features of acute generalized exanthematous pustulosis caused by hydroxychloroquine in rheumatology patients and exploration of gene mutations.
Front Med (Lausanne). 2023 Apr 6;10:1161837. doi: 10.3389/fmed.2023.1161837. eCollection 2023.
5
COVID-19 infection leading to acute pustular dermatoses.
Arch Dermatol Res. 2023 May;315(4):685-697. doi: 10.1007/s00403-022-02450-z. Epub 2022 Nov 1.
6
Acute generalized exanthematous pustulosis: a complication of COVID-19 infection or therapy?
J Cosmet Dermatol. 2022 May;21(5):1784-1787. doi: 10.1111/jocd.14930. Epub 2022 Apr 5.
7
Cutaneous manifestations of COVID-19 among healthcare workers: A Case report and literature review.
Clin Case Rep. 2022 Mar 16;10(3):e05571. doi: 10.1002/ccr3.5571. eCollection 2022 Mar.
8
Severe and life-threatening COVID-19-related mucocutaneous eruptions: A systematic review.
Int J Clin Pract. 2021 Dec;75(12):e14720. doi: 10.1111/ijcp.14720. Epub 2021 Sep 28.
9
A systematic review of the histopathologic survey on skin biopsies in patients with Corona Virus Disease 2019 (COVID-19) who developed virus or drug-related mucocutaneous manifestations.
Exp Dermatol. 2021 Sep;30(9):1233-1253. doi: 10.1111/exd.14384. Epub 2021 May 24.
10
A systematic review on treatment-related mucocutaneous reactions in COVID-19 patients.
Dermatol Ther. 2021 Jan;34(1):e14662. doi: 10.1111/dth.14662. Epub 2020 Dec 26.
本文引用的文献
1
Cutaneous manifestations in COVID-19: Lessons learned from current evidence.
J Am Acad Dermatol. 2020 Jul;83(1):e57-e60. doi: 10.1016/j.jaad.2020.04.094. Epub 2020 Apr 24.
2
Characterizing the adverse dermatologic effects of hydroxychloroquine: A systematic review.
J Am Acad Dermatol. 2020 Aug;83(2):563-578. doi: 10.1016/j.jaad.2020.04.024. Epub 2020 Apr 11.
3
Hydroxychloroquine and ivermectin: A synergistic combination for COVID-19 chemoprophylaxis and treatment?
J Am Acad Dermatol. 2020 Jun;82(6):e221. doi: 10.1016/j.jaad.2020.04.017. Epub 2020 Apr 10.
4
Does hydroxychloroquine combat COVID-19? A timeline of evidence.
J Am Acad Dermatol. 2020 Jul;83(1):e33-e34. doi: 10.1016/j.jaad.2020.04.031. Epub 2020 Apr 10.
5
Generalized pustular figurate erythema: A newly delineated severe cutaneous drug reaction linked with hydroxychloroquine.
Dermatol Ther. 2020 May;33(3):e13380. doi: 10.1111/dth.13380. Epub 2020 Apr 16.
6
Hydroxychloroquine-induced acute generalized exanthematous pustulosis with positive patch-testing.
Indian J Pharmacol. 2015 Nov-Dec;47(6):693-4. doi: 10.4103/0253-7613.169589.
Zotero 插件